Akoya Biosciences, Inc. SEC Filings

Key take-aways from the Form 4 filed for Akoya Biosciences (AKYA)

• Reporting person: Director Myla Lai-Goldman.
• Transaction date: 07/08/2025, which is the closing date of the merger between Akoya Biosciences and Quanterix Corporation.
• Merger mechanics: Each outstanding AKYA common share was converted into (a) 0.1461 share of Quanterix common stock and (b) $0.38 in cash (together, the “Per Share Merger Consideration”). The consideration may be adjusted under the Merger Agreement.
• Common shares disposed: 20,000 AKYA shares were relinquished under Transaction Code J (other). The director now reports 0 AKYA shares beneficially owned.
• Stock options cancelled: Four tranches of options (38,993 @ $18.10; 30,549 @ $11.24; 56,322 @ $5.70; 50,000 @ $2.01) were accelerated and automatically terminated for no consideration, in line with the merger terms, because their exercise prices equalled or exceeded the merger consideration. Total options affected: 175,864.
• Post-merger structure: Akoya survives as a wholly-owned subsidiary of Quanterix, and AKYA securities cease to exist as standalone equity.

The filing is strictly a compliance disclosure reflecting the consummation of the merger and the resulting elimination of the director’s direct holdings in AKYA equity instruments.

On 8 July 2025, Akoya Biosciences, Inc. filed Post-Effective Amendment No. 1 to five outstanding Form S-8 registration statements that together covered its 2015 and 2021 equity incentive and employee stock purchase plans. Following the same-day completion of its merger with Quanterix Corporation, Akoya—now a wholly owned Quanterix subsidiary—has terminated the related offerings and withdrawn from registration all unissued shares originally reserved under these plans. The action removes up to roughly 15.4 million shares of Akoya common stock from the public markets, eliminating any residual equity overhang and fulfilling the undertaking required under Rule 478 after a change-of-control transaction.

The filing is a Post-Effective Amendment to five prior Form S-8 registration statements covering an aggregate approximately 15.4 million shares of Akoya Biosciences common stock reserved for issuance under the company’s 2015 and 2021 equity and ESPP plans. On 8 July 2025 Akoya completed its previously announced merger with Quanterix Corporation, becoming a wholly owned subsidiary. Because the merger terminated any further offering of Akoya securities, the company is using this amendment to withdraw and remove from registration all unissued shares under the referenced S-8s. No new securities are being registered, and the filing contains no financial results, capital raising, or operational updates. The sole signatory is Treasurer Vandana Sriram pursuant to Rule 478.

For investors, this action is largely administrative and neutral: it formally closes out equity incentive plans that ceased to exist once Akoya was acquired. The amendment neither affects Quanterix’s share count nor provides insight into the financial performance of either company.

Akoya Biosciences, Inc. (AKYA) filed Post-Effective Amendment No. 1 to five prior Form S-8 registration statements that collectively covered roughly 15.4 million shares reserved for the company’s 2015 and 2021 equity incentive and employee stock purchase plans. The amendment withdraws and removes from registration all shares that remained unissued under those plans.

The action follows the closing of the merger with Quanterix Corporation on 8 July 2025, under which Wellfleet Merger Sub, Inc. merged into Akoya, leaving Akoya as a wholly owned subsidiary of Quanterix. Because the company’s independent equity programs have been terminated, the related offerings under the S-8 registrations have also ended, triggering the undertaking to deregister the remaining securities.

The filing is signed on behalf of Akoya by Treasurer Vandana Sriram pursuant to Rule 478, and no additional signatures are required.

Akoya Biosciences, Inc. (AKYA) has filed Post-Effective Amendment No. 1 to five prior Form S-8 registration statements covering a combined 15,413,349 shares that were reserved for issuance under the company’s 2015 and 2021 equity compensation and employee stock purchase plans. The amendment formally withdraws any shares that remain unissued under those plans.

The filing follows the closing of the previously announced merger whereby Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, merged with and into Akoya on 8 July 2025. Akoya survived the transaction as a wholly-owned subsidiary of Quanterix. Because Akoya is no longer an independent public company, its equity incentive plans and related share offerings have been terminated and the SEC registrations are no longer required.

Operationally, the amendment is an administrative step with no impact on outstanding Akoya shares already converted in the merger. It eliminates potential registration maintenance costs and SEC reporting obligations tied to the now-obsolete plans. The document provides no new financial results, outlook, or merger consideration details—investors should rely on prior merger communications for those specifics.

Akoya Biosciences, Inc. ("Akoya") filed Post-Effective Amendment No. 1 to five previously effective Form S-8 registration statements to deregister any shares that remain unissued under its 2015 and 2021 equity compensation plans.

The action follows the closing of the merger with Quanterix Corporation on 8 July 2025, in which Wellfleet Merger Sub, Inc. was merged with and into Akoya, leaving Akoya as a wholly owned subsidiary of Quanterix. Because Akoya’s stand-alone equity offerings have terminated, the company is withdrawing the following original S-8 share pools:

• Reg. No. 333-285859 – 2,478,606 EIP shares & 247,860 ESPP shares
• Reg. No. 333-277648 – 2,455,886 EIP shares & 245,588 ESPP shares
• Reg. No. 333-270312 – 1,914,409 EIP shares & 191,440 ESPP shares
• Reg. No. 333-263548 – 1,871,205 EIP shares & 187,120 ESPP shares
• Reg. No. 333-255468 – 3,920,487 2015 EIP shares, 1,727,953 2021 EIP shares & 172,795 ESPP shares

This is an administrative filing; it does not affect the merger consideration already received by former Akoya shareholders, nor does it introduce new financial metrics. The amendment is signed by Treasurer Vandana Sriram on behalf of Akoya and relies on Rule 478 to omit additional signatures.

Royal Bank of Canada ("RBC") has filed a 424B2 preliminary pricing supplement for a new structured product: Auto-Callable Contingent Coupon Barrier Notes linked to the common stock of Apple Inc. (AAPL). The two-year senior unsecured notes (Series J) are expected to price on July 22 2025, issue on July 25 2025 and mature on August 27 2026, unless automatically called earlier.

Key commercial terms

• Denomination: $1,000 minimum, CUSIP 78015QSS1
• Contingent coupon: 0.80% monthly (9.60% p.a.) paid only if AAPL’s closing price on the relevant observation date ≥ 78% of the initial price (Coupon Threshold).
• Automatic call: Beginning six months after trade date, the notes are redeemed at par + current coupon if AAPL ≥ initial price on any monthly call observation date.
• Principal barrier: If not called, full principal is repaid only if final AAPL price ≥ 78% of initial; otherwise holders receive AAPL shares worth the depressed value (physical delivery amount = $1,000 / initial price).
• Initial estimated value: $920.24 – $970.24 per $1,000, below the 100% public offering price; underwriting discount 1.50%.
• The notes are not FDIC/CDIC insured, bail-inable, or exchange-listed and are subject to RBC credit risk.

Illustrative outcomes: If AAPL falls ≥22.01% at maturity and the notes were never called, investors suffer proportionate equity loss (e.g., –50% AAPL leads to $500 value). Upside in AAPL above par is forfeited; maximum return equals accumulated coupons.

Risk disclosure highlights: potential loss of principal, possibility of zero coupons, limited liquidity, valuation below issue price, tax uncertainty under U.S. rules, and conflicts of interest as RBCCM acts as both underwriter and calculation agent.

Akoya Biosciences, Inc. (AKYA) has been the subject of a Form 25 filing submitted by Nasdaq Stock Market LLC on 2025-07-08. The Exchange states that it has satisfied the requirements of 17 CFR 240.12d2-2(b), allowing it to strike the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies reasonable grounds for the filing and the notification is signed by Tara Petta, AVP. The form also references compliance with the voluntary withdrawal provisions of 17 CFR 240.12d-2(c).

Once effective, Akoya’s shares will no longer trade on Nasdaq and the Section 12(b) registration will terminate, severely reducing exchange-based liquidity and regulatory reporting obligations.

Transaction overview: On July 8, 2025, Akoya Biosciences, Inc. (“Akoya”) completed its merger with Wellfleet Merger Sub, a wholly-owned subsidiary of Quanterix Corporation, becoming a wholly-owned subsidiary of Quanterix pursuant to the Amended and Restated Agreement and Plan of Merger dated April 28, 2025.

Merger consideration: Each Akoya share was converted into (a) 0.1461 share of Quanterix common stock and (b) US $0.38 in cash, with caps that limit Quanterix’s total share issuance to 19.99 % of its pre-closing shares and aggregate cash to US $20 million; fractional shares will be paid in cash. Vested RSUs and in-the-money options were cancelled for the right to receive the same per-share consideration, while unvested RSUs rolled over into Quanterix-settled awards. Underwater options were terminated without payment.

Capital structure changes: Concurrent with closing, Akoya repaid in full and terminated its 2020 MidCap Credit and Security Agreement, ended its 2021 Employee Stock Purchase Plan, and provided notice to terminate its 2022 Equity Distribution Agreement with Piper Sandler. Akoya’s certificate of incorporation and bylaws were amended and restated to match those of the surviving subsidiary.

Listing & reporting status: Akoya requested Nasdaq to suspend trading on July 8, 2025 and will file Form 25 to delist its common stock, followed by Form 15 to terminate Exchange Act registration and reporting obligations.

Governance & management: All pre-merger directors and executive officers resigned. Masoud Toloue became sole director and President; Vandana Sriram (Treasurer), Laurie Churchill (Secretary) and Brian Keane (Assistant Secretary) filled the remaining officer roles.

Investor implications: Shareholders gain immediate liquidity and continued upside through Quanterix equity while Akoya eliminates its outstanding debt. However, AKYA will no longer trade independently, and minority holders’ future value will be tied to Quanterix’s performance.